

JNJ-38877605

Catalog No: tcsc0031



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

943540-75-8

Formula:

$C_{19}H_{13}F_2N_7$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

c-Met/HGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 30 mg/mL (79.50 mM)

Observed Molecular Weight:

377.35

Product Description

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC₅₀ of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and


serine-threonine kinases.

IC50 value: 4 nM [1]

Target: c-Met

in vitro: JNJ-38877605 shows more than 600-fold selectivity for c-Met compared with more than 200 other diverse tyrosine and serine-threonine kinases and also potently inhibits HGF-stimulated and constitutively activated c-Met phosphorylation in vitro. [1] In EBC1, GTL16, NCI-H1993, and MKN45 cells, JNJ-38877605 (500 nM) leads to a significant reduction of phosphorylation of Met and RON, another key player in invasive growth [2]. A recent study shows that JNJ-38877605 is involved in modulating secretion of IL-8, GRO α , uPAR and IL-6 in GTL16 cells [3].

in vivo: In mice bearing established GTL16 xenografts, JNJ-38877605, dosed orally with 40 mg/kg/day for 72 hours, results in a statistically significant decrease in the plasma levels of human IL-8 (from 0.150 ng/mL to 0.050 ng/mL) and GRO α (from 0.080 ng/mL to 0.030 ng/mL). While concentrations of uPAR in the blood become reduced to more than 50% at the same dose [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!